Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Effects of short (6 months) and long (18 months) term treatment with gh-receptor antagonist pegvisomant (peg) on rhythm disturbances in acromegaly
Renata Auriemma, Federico II University of Naples, Italy
Long term treatment with pegvisomant in acromegalic patients results in significant improvement in cardiac rhythm, with low incidence of adverse events
Cardiovascular risk factors in treatment-resistant, active and long-term acromegaly: comparison to matched data from the general population and the effect of disease control
Christian Berg, University Hospital of Essen, Germany
In addition to being associated with an increase risk of cardiomyopathy, patients with acromegaly also experience a significant increase in the risk of CHD.
Pegvisomant significantly reduces the risk of CV risk in acromegalic patients, particularly in patients with normalised IGF-1 levels
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.